Resverlogix exceeds full enrollment for pivotal phase 3 BETonMACE clinical trial
Resverlogix announced it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The goal of the trial is to confirm the effect of Resverlogix’ lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 DM and low HDL. March 19, 2018